Long-term Use of Controlled-release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study

Portenoy, Russell K.; Farrar, John T.; Backonja, M.; Cleeland, Charles S.; Yang, K.; Friedman, Michael; Colucci, Salvatore V.; Richards, P.

doi:10.1097/ajp.0b013e31802b582f

Cited by 178 publications

(127 citation statements)

References 29 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Although the mean duration of therapy in this trial was only 37.24 days, a separate study carried out over a 3-year period demonstrated that oxycodone CR can achieve adequate, longer-term pain management of non-cancer pain, without requiring a further increase in dose (Portenoy et al 2007). …”

Section: Discussionmentioning

confidence: 99%

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Ferrarese

Becchimanzi²,

Bernardo³

et al. 2008

TCRM

View full text Add to dashboard Cite

Objective:To investigate the possible role and tolerability of high-dose (Ͼ160 mg/day) oxycodone controlled release (CR) for the treatment of cancer and non-cancer pain. Design: 227 patients with cancer or non-cancer pain were enrolled in an open-label, multi-center, Italian study in order to assess the adequacy of their existing pain management (using a numerical rating scale [NRS]) and the possible benefi t high-dose oxycodone CR may offer patients experiencing uncontrolled pain. Results: Pain was poorly controlled at baseline, with only 18.1% of patients reporting adequate pain relief (NRS Ͻ3.5). All other patients reported uncontrolled pain, with an average NRS of 7.81. At baseline assessment, 47.89% of patients had been in pain for up to 3 months, 32.82% for 3-6 months, and 19.19% for more than 6 months. After baseline assessment, patients were switched to oxycodone CR monotherapy. The starting dose was individualized to each patient and titrated up over a 3-to 4-day period until effective pain management was achieved. Treatment was continued for an average of 37.24 days during the study. Pain control (fi nal mean NRS of 2.85) was attained with an average dose of oxycodone CR 221.84 mg/day. Standard adverse events (including constipations, nausea, and vomiting) were recorded in 39.64% of patients receiving high-dose oxycodone CR monotherapy. Side-effects tended to subside after the initial week of treatment and did not result in any participants leaving the study. Conclusion: High-dose oxycodone CR can achieve rapid and effective management of moderate to severe cancer and non-cancer pain with minimum side-effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Ferrarese

Becchimanzi²,

Bernardo³

et al. 2008

TCRM

View full text Add to dashboard Cite

show abstract

“…Besides known opioid side effects, it has been associated with development of dysgeusia, dry mouth, gastro paresis in diabetics and loss of consciousness has been reported with accidental overdose [58].…”

Section: Side Effects Related Specifically To Different Opioids Fentanylmentioning

confidence: 99%

Rare and Serious Side Effects in Chronic Pain after Opioids

Bajwa¹

2012

J Pain Relief

View full text Add to dashboard Cite

Opioids have been used since centuries for relief of both acute and chronic pain. The known and established side effects associated with usage of opioids such as nausea, vomiting, pruritis, respiratory depression, constipation, urinary retention, sedation and addiction constitute the main limitation while titration of the doses. Besides these established side effects, newer side effects of opioids are being reported with prolonged usage which has been rarely mentioned in the literature. These side effects are diverse in their presentation and have virtually involved every organ system ranging from cardio-vascular, pulmonary, immunologic, endocrine, musculo-skeletal, central nervous system, peripheral nervous system and so on. The present review elaborates in detail about these new serious side effects which have been reported rarely till now.

show abstract

“…Tolerance represents the need to increase opioid dosage to obtain the same effect of pain relief. Certain population subgroups, such as those with a history of drug abuse, are at higher risk of opioid addiction 50 . Dependency problems are more commonly associated with non-cancer pain [51][52][53] ; however, a recent systematic review of clinical trials involving patients with long-term noncancer pain receiving opioids showed that signs of dependence and misuse were relatively low and reported in 0.05% and 0.43% of patients, respectively 18 .…”

Section: Dependencymentioning

confidence: 99%

Opioids: a two-faced Janus

Ahlbeck

2011

Current Medical Research and Opinion

View full text Add to dashboard Cite

Background: Long-term pain is a debilitating condition that is costly to treat and has a significant impact on patient quality of life. Classical opioids have been used for the treatment of pain for centuries and are one of the most effective drug classes available for acute severe pain and long-term pain. However, concerns regarding adverse effects, tolerance to analgesic effects and the potential for addiction have resulted in a reluctance to prescribe and use opioids for the management of long-term non-cancer pain. Adverse events, including gastrointestinal side effects such as constipation, nausea and vomiting, and central nervous system side effects such as sedation are responsible for as many as one in five patients discontinuing opioid treatment, often leading to inadequate pain relief and poor patient quality of life. Therefore, new analgesic therapies are needed that are associated with fewer adverse effects, whilst providing sustainable pain relief for patients with long-term pain.

show abstract

Long-term Use of Controlled-release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study

Abstract: These registry data demonstrate that a subgroup of patients with noncancer pain experienced prolonged relief with tolerable side effects and modest need for dose escalation during long-term therapy with CR oxycodone.

Cited by 178 publications

References 29 publications

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Rare and Serious Side Effects in Chronic Pain after Opioids

Opioids: a two-faced Janus

Contact Info

Product

Resources

About